Genzyme`s Biologic Campath (alemtuzumab) Receives Approval in the U.S.
Study suggests stem cell transplants may delay disability longer than some other medications in patients with active secondary progressive multiple sclerosis.
Genzyme's Biologic Campath (Alemtuzumab) Sodium Receives Approval in the U.S.
Genzyme's Lemtrada (alemtuzumab) Receives Approval in the U.S.
Genzyme's Biologic Lemtrada (Alemtuzumab) Receives Approval in the U.S.
Genzyme's Biologic Campath (Alemtuzumab) Receives Approval in the U.S.
Genzyme`s Biological Alemtuzumab Receives Approval In the US
Genzyme`s Campath (Alemtuzumab) Receives Supplimental Approval in US
Genzyme`s Lemtrada (Alemtuzumab) Receives Supplimental Approval in US
MabCampath (alemtuzumab) - Risk of Haemophagocytic Lymphohistiocytosis, Stroke (including ischaemic and haemorrhagic stroke), and Glomerulonephritis - Recalls and safety alerts